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a b s t r a c t
Oleoyl-estrone (OE) is a powerful anti-obesity compound that decreases food intake, decreases insulin
resistance and circulating cholesterol. OE stimulates a severe loss of body fat by decreasing adipose tissue
lipid synthesis and maintaining lipolysis. Therefore, the body economy loses lipid energy because energy
expenditure is maintained. This study analyses the discrepancy between OE effects and the distribution
of labelled OE in plasma.
Estrone radioimmunoassay of organic solvent plasma extracts of rats treated with OE showed the mas-
sive presence of acyl-estrone, but saponification did not release estrone, but containing similar unknown
compound. Analysis of label distribution in plasma after oral gavages of 3H-OE showed the presence of a
more hydrophilic compound than OE or any estrogen as well as 3H2O, formed from 3H-OE in the acidic
stomach medium. OE was not attached to a specific transporter in plasma. Through serum HPLC analysis
we found W, a labelled derivative more hydrophilic than OE or estrone. The results were confirmed using
14C-OE. HPLC–MS/MS studies showed that plasma OE levels were one order of magnitude lower than
those of W.
When liver cell cytosols from rats laden with 3H-OE were incubated with nuclei from untreated rats, the
OE-derived label (i.e., Ws) was found attached to nuclear DNA. Neither estradiol nor estrone interfered
with its binding. W is a fairly hydrophilic compound of low molecular weight containing the estrone
nucleus, but it is not an ester because saponification or esterases do not yield estrone as OE does. It is
concluded that OE acts through its conversion to W, its active form; which binds to a nuclear receptor
different from that of estrogen. The estimated W serum levels are proportional to the pharmacological
OE effects in vivo. We postulate W as a new type of hormone that exerts the full range of in vivo effects
thus far attributed to OE. The full identification of W is anticipated to open the way for the development
of new OE-like anti-obesity drugs.
© 2011 Elsevier Ltd. All rights reserved.
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1. Introduction
1.1. Oleoyl-estrone, nature and effects
Oleoyl-estrone (OE) is a powerful slimming agent [1,2]; it
decreases food intake but, at the same time, maintains energy
expenditure [3]. The energy gap is closed by the mobilisation of
white adipose tissue (WAT) reserves [4], sparing body protein [3].
OE also decreases the high insulin [5] and hyperlipidemia of obese
rats [6], particularly of cholesterol [6,7]. Liver glycogen is main-
tained (or increased) by OE even under a severe loss of body lipid
energy [5], also maintaining normoglycemia [8].
Treatment with OE is more effective in male than in female rats
[9] and induces weight losses even under treatment with cafeteria
diet [10] or other hyperlipidic diets [4,11]. A peculiarity of OE treat-
ment is the permanent loss of fat, suggesting a role as ponderostat
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signal for the estrone ester [12]. When OE is given in combination
with a 3-adrenergic agonist, the WAT wasting effects are markedly
increased [13], with additive effects [14]. Similar, but less marked,
additive effects were also observed with dexfenfluramine, sibu-
tramine [15] and a thiazolidinedione [16], with opposing effects
on WAT lipid integrity, but coincident in maintaining glycemia. In
fact, OE slightly decreased UCP1 expression in brown adipose tissue
[17], but also increased the expression of this uncoupling protein
in some WAT sites [14].
The effects of OE on lipids can be summarised in the inhibition
of lipogenesis in WAT [18] (but not in liver, which has sufficient
glucose available) [19]. These effects include decreased lipoprotein
lipase expression and activity in WAT (and hepatic lipase in liver),
but increased activity in muscle [6], whilst intracellular lipolysis
is unaffected [18]. SREBP1c is involved in mediating these effects
[19]. In the case of the liver, lipogenesis is exacerbated by cor-
ticosteroids, which revert the overall wasting of energy induced
by OE [20]. Oleoyl-estrone induces a counter-regulatory increase
in ACTH and corticosterone levels [21], with increased corticos-
teroid activity and turnover [22]. This increase is largely due to
adrenal hypertrophia and increased expression of the entire corti-
costeroid synthetic pathway [23] but is also due to increased liver
corticosteroid disposal via 5-reductase [22]. Treatment with OE
reduces the WAT expression of most cytokines [5,14], especially
leptin [5]. The expression of adiponectin is also decreased by OE
[14]. Although the effects of OE on WAT are fairly diverse depend-
ing on the WAT site, one effect of OE is apoptosis [24]. Table 1 shows
the principal effects of OE treatment and its metabolic actions.
1.2. OE methodology
OE is a wax-like lipophilic ester that tends to attach to any
surface (including dissolved proteins) in aqueous media. OE is par-
ticularly non-reactive and is a difficult target for ionisation and
analysis by mass spectrometry. In addition, characterisation of its
estrogenic moiety is not an exclusive OE marker because plasma
and tissues contain a number of estrogens with similar derivative-
forming reactions. The oleoyl moiety is even less promising because
of its high abundance in rat lipids [24].
We developed a method that allowed us to measure estrone
(fatty) acyl-esters: after organic extraction of plasma, the dried lipid
extract was saponified with hydroalcoholic KOH, and the released
free estrone was again extracted and analysed by radioimmuno-
analysis (RIA) [25]. A modified method was used for the analysis of
acyl-estrone in foods [26]. A much improved version of this method
was developed for the estimation of acyl-estrone in dairy products
[27]. An antibody that does not react with estradiol was used to
measure the evolved estrone and allowed us to assign the levels
of “acyl-estrone” measured to OE. In fact, values measured in rats
injected with OE were higher than those of controls [5,12,28].
Previous MS studies have shown that OE is present both in
plasma and adipose tissue fat [3], but its low ionisation makes its
detection and analysis a difficult task.
1.3. Specificity of OE and objectives of the present study
The idea of specificity of the molecule to elicit the observed
marked metabolic changes was further analysed by preparing
a number of structurally similar molecules (mainly estradiol or
estrone fatty acid esters) [29]. The results showed that the sought
in vivo effects were optimal only for OE. Saturation of the fatty acid,
or its shortening, hydroxylation in C17 or change of union (ether,
amide) of the acyl moiety with estrone all resulted in decreases or
loss of slimming effectiveness. Only oleoyl-diethyl-stilbestrol gave
similar results to OE in vivo [29].
Table 1
Estimation of 14C- and 3H-labelled OE derivative (containing the estrone nucleus)
in plasma of adult male rats subjected to a gavage of 10 nmol/g OE 2 h before the
analysis.




MBq 3.96 ± 0.41 0.952 ± 0.101
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MBq 1.23 ± 0.13 0.295 ± 0.031

























nM 413 ± 144
In spite of all indirect proof and the specificity of the link
between OE structure and physiological/pharmacological effects,
the application of the described methodology produced a number
of inconsistencies when the measured levels were cross-analysed
with all of the available data:
(a) The majority of the problems posed by the extreme lipophilia
of OE are likely overcome in biological systems by the binding
of OE to a protein transporting system, analogous to those of a
number of steroid hormones [30]
(b) Early analyses of plasma using mass spectrometry showed the
presence of OE, but at much lower levels compared with the
RIA-derived data.
(c) The consequences of a change in the supplier of the estrone
antibody (the one we used was discontinued) were impossi-
ble to overcome, as all new antibodies were ineffective. The
analytical results were no longer reproducible.
(d) The use of tritium-labelled OE (in the estrone moiety) indicated
that in plasma, the levels of label (whose only source was the OE
estrone moiety) were fairly higher than the measured levels of
“acyl-estrone”, even when other estrone-containing molecules
(free estrone, estrone sulphate) were taken into account.
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The main objective of this study was to clarify a number of
methodological inconsistencies that seriously hindered the anal-
ysis of the mechanism of action of OE. Initially, the search was
centred on the OE receptor and on the carrier “transporting protein”
that allowed such a lipophilic molecule as OE to be transported in
the hydrophilic plasma medium, even considering its attachment to
lipoproteins [31]. However, the key aim was to understand whether
OE acts as a signal by itself or is transformed into a more specific –
and powerful – signal before being transported by the bloodstream
and acting on OE target tissues.
2. Experimental
2.1. The search for a plasma OE-transporter
2.1.1. In vivo analysis of labelled OE in plasma of rats receiving
labelled OE gavages
Large male Wistar rats (400–450 g) were used. All animal han-
dling procedures were approved by the Animal Management Ethics
Committee of the University of Barcelona and were in full compli-
ance with the norms and directives of the EU, Spain and Catalonia.
The rats were given the standard working OE dose: a single
10 nmol/g gavage of OE (OED, Barcelona, Spain) in 0.2 mL of sun-
flower oil [32]. The rats were then killed by decapitation, and the
blood was recovered and allowed to clot. The serum was then sep-
arated by centrifugation, frozen and stored at −80 ◦C until needed.
Other rats (controls) received the vehicle alone. Tritium-labelled
OE was synthesised by us [3] from 3H-estrone (NEN, Bad Neuheim,
Germany) and oleoyl-chloride (Sigma).
The i.v. [33] or oral [34] administration of labelled OE resulted
in an increase of circulating label in plasma. The esterified estrone
content of plasma in OE-laden rats also dramatically increased [35].
Similarly, we found that the proportion of circulating acyl-estrone
was increased in humans with higher body fat content [36], but
not in the morbidly obese [37]. The extreme lipophilic nature of OE
precludes its simple transport as such, which is a problem shared
by triacylglycerols, cholesterol and even non-esterified fatty acids.
Consequently, we searched for an OE-carrier protein or OE trans-
porter (OET).
2.1.2. OE and lipoproteins
The close relationship of OE with lipoprotein fractions [31,38]
and its relative binding to these lipoproteins were countered by the
easy washing out of label from native plasma lipoprotein fractions
from rats loaded with 3H-OE, separated by size exclusion chro-
matography in Sephacryl S200 columns using a 50 mM phosphate
buffer pH 7.2 containing NaCl 150 mM. Most of the label was eluted
with the front, and the label was retained in the high MW pro-
tein fractions (i.e., lipoproteins). When repeatedly passed through
the column, the label increasingly eluted with the front and finally
could be entirely recovered in the low MW section in spite of its
initial attachment to lipoproteins.
Classical lipoprotein separation is performed through ultracen-
trifugation in a saline gradient [39]. However, this approach results
in the distribution of OE label between the main lipoprotein classes
and the lipoprotein-free serum fraction [38,40]. These data sug-
gested that the OET was indeed a small MW protein naturally
attached in a loose way to larger lipoproteins but was easily washed
out of them. This behaviour hinted at both small size and a relative
polarisation with lipophilic and hydrophilic domains.
OE can be easily separated (and visualised and counted) from
estrone by TLC on silica gel plates using a mobile phase of hex-
ane/ethyl ether/acetic acid (20:5:1) because the rf for estrone in
this system was 0.25 and 0.52 for OE. Analysis of plasma organic
phase extracts showed practically no estrone nor OE, with most
of the label remaining at the origin. This result was initially inter-
preted as proof that most of the OE in plasma was bound to OET
and was unable to elute in such a hydrophobic running phase. We
already expected low estrone levels because plasma estrone is in
the 0.2–2 nM range [35,41]; the values expected for OE were much
higher [35].
2.1.3. In vitro loading of plasma with labelled OE
Celite (World Minerals, Rubí, Spain) was suspended in a
methanol suspension of 3H-OE, and after 1 h incubation, the
methanol was evaporated by centrifugation under vacuum. The
high surface area of celite was thus heavily impregnated with OE;
repeated washings in water resulted in negligible losses of label. A
suspension of 3H-OE-celite was added to rat plasma and incubated
for 12 h at 35 ◦C. The objective was to allow OE to be loaded to
OET (or interchanged with cold OE-OET). Extraction of the plasma
with trichloromethane–methanol (2:1) or hexane resulted in the
practical washing of all label to the organic phase. Cold-ethanol
precipitation [42] also yielded a Cohn’s fraction III supernatant
practically devoid of label.
However, extraction of plasma from 3H-OE-laden rats with
trichloromethane/methanol (2:1) [43] resulted in the retention of
only 42% of the label in the organic phase, in contrast with 81% for
a suspension of labelled OE (of about 80–85% purity) in water, with
the rest remaining in the aqueous phase.
2.1.4. Plasma protein fractioning and OE
Separation of plasma fractions using cold ethanol, according to
the classical Cohn procedure [42], showed that most of the plasma
label remained in the supernatant of Cohn’s fraction III. The OET
was soluble in ethanol/water 1:1. Extraction of this supernatant
with trichloromethane/methanol diluted with water yielded a 42%
label in the organic phase, which was the same as the result that
was obtained with native plasma. Extraction of plasma using a more
apolar solvent, hexane, resulted in lower label yields (23%) in the
organic phase; however, this recovery decreased to only 6% in the
Cohn’s fraction III supernatant, which are values that are markedly
different from those of OE.
Using either the Cohn’s fraction III supernatant or the front
eluates of Sephacryl S200 columns (Sigma) from 3H-OE-laden rat
plasma, a number of protein identification analyses were per-
formed:
(1) Lyophilisation resulted in the loss of variable amounts of label,
but in general only about 60% of tritium was lost. It was
assumed that this was simply tritiated water, confirmed later
as explained further on this paper. The remaining label corre-
sponded roughly to that extracted with organic solvents.
(2) The lyophilised extract was subjected to 2 h of heat (150 ◦C)
in order to denature the OET. However, TLC separation of the
organic extract showed that neither estrone nor OE was present,
and all label remained unchanged at the origin. It is almost
impossible for a protein to maintain its structure unaltered
and remain bound to its ligand when subjected to such high
temperatures.
(3) The use of other protein-denaturing agents, such as perchloric
acid, tannin, trichloroacetic acid, or heavy metal salts (uranyl-
nitrate, lead acetate), yielded the same results: OE was not
released. Most proteins are denatured and release their ligands
when subjected to at least a few of the denaturing agents listed.
(4) The addition of acetone (2:1) resulted in no precipitate. Ace-
tone extracts of plasma also yielded all label in the supernatant
(after correcting for the label occluded with solvent in the pre-
cipitate). Proteins and peptides precipitate under high acetone
concentrations.
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(5) Analysis of these supposed OET fractions by MALDI-TOF
showed no results at all; i.e., no protein or compound with a
MW higher than 1 kDa was present in the samples analysed.
2.1.5. Protein separation and fate of plasma OE-derived label
Ultrafiltration through molecular sieves of 10 kDa and 3 kDa of
both Sephacryl eluates and Cohn’s fraction III supernatants resulted
in practically all label passing through. Ultrafiltration of plasma
diluted with saline resulted in the retention of a small but highly
variable proportion of label (13–34%), which was probably loosely
attached to large lipoproteins.
Polyacrylamide gel electrophoresis of concentrated Sephacryl
eluates and Cohn’s fraction III supernatants (as well as of crude
plasma) from rats treated with 3H-OE resulted in practically all of
the label remaining in the starting wells. The rest of the label (prob-
ably tritiated water) was diffusely distributed in the buffer front, in
zones with no significant protein presence (as assessed by AgNO3
or Coomassie blue staining).
The data gathered clearly demonstrated that there was no free
OE in plasma and that OE was not carried by a specific protein trans-
porter. In addition, a sizeable part of the label, lost by lyophilisation,
may correspond to tritiated water or a similar volatile compound
of low MW and is probably unrelated to OE function and effects.
OE behaves in very different ways with respect to solvent extrac-
tion than the compound(s) bearing the tritium label which we can
consider directly related to the physiological or pharmacological
actions of OE. This active form of OE has a very low MW, is more
hydrophilic than OE and is thermically stable, but can nonetheless
be extracted with organic solvents.
2.2. HPLC–MS/MS analyses
2.2.1. Differentiation of OE and estrone
To clarify the situation, we decided to measure OE
by HPLC–MS/MS, using two different strategies: (a) the
saponification–derivatisation system used previously, but instead
measuring dansyl-estrone by HPLC–MS/MS and (b) searching for
methodological approaches or conditions that allowed us to ionise
– albeit partially – the OE molecule and/or break it up in the mass
spectrometer and compare the fragments’ family with that of OE.
The study was first developed using pure standards. Previous
analyses showed that about 98–99% of 3H-OE was extracted with
the organic phase, almost irrespective of the solvent used. Stan-
dards of OE, estrone or other estrogens (Steraloids, Newport, RI,
USA, and Sigma, St Louis, MO, USA) were used; deuterated estra-
diol and estrone (CDN Isotopes, Pointe Claire, ON, Canada) were
also used as internal standards. Chromatographic-grade solvents
were from Riedel de Haën (Seelze, Germany). Deuterated OE was
synthesised [3] from oleoyl-chloride and deuterated estrone and
later purified by normal phase chromatography on silica columns
(eluted with hexane ethyl acetate/acetic acid; 19/1/1). The rf for
estrone was 0.22, that of OE was 0.55 and oleic acid was 0.73. The
structure and integrity of OE was checked by NMR dissolved in
CDCl3.
We used a LC–MS/MS (Varian, Palo Alto, CA, USA) with an instru-
mental setup consisting of: 210 pump with an on-line degassifier,
410 autosampler and 1200L triple quadrupole mass spectrometer
equipped with an electrospray ionisation (ESI) source operated in
positive ion mode.
Full identification of the OE and estrone peaks was performed
by changing the conditions of elution and the sensitivity/ionisation
and breakup of the molecules. In the final (definitive) analytical
method developed, chromatographic separation was carried out
using an Atlantis column 50 mm × 2.1 mm × 3 m (Waters, Milford,
USA). The solvents were: (A) 10 mM ammonium formiate in 1 g/L
formic acid and (B) 1 g/L formic acid in acetonitrile. The flow rate
was 0.3 mL/min. Standards of OE and estrogens were separated
using this system as shown in Fig. 1. However, the concentra-
tions needed to show measurable peaks were much higher than
those found in serum for most estrogens. Consequently, a mod-
ified dansyl-chloride (Sigma) derivatisation method was used to
measure the serum levels of estrone and its oxidised derivatives
[44].
2.2.2. Analysis of serum samples
Triplicate serum samples (0.400 mL each) were used; one of
the samples was duped with 0.010 mL of 50 nM deuterated OE
(d4-estrone), 50 nM free d4-estrone or 25 nM free d4-estradiol
as internal standards. These samples were extracted with 2 mL
of chilled dichloromethane, and after centrifugation, the organic
phase was dried under a gentle stream of nitrogen. The dry residues
were dissolved in 0.200 mL methanol, and 0.020 mL was injected
into the HPLC.
OE was measured in serum without derivatisation, assuming
(from the RIA-based method data) that its concentration in plasma
was in the 100 nM range. The final conditions for OE direct analysis
in plasma organic extracts allowed the measurement of concentra-
tions >20 nM. Under these conditions, no OE was found in rat serum
from either rats having received an OE load or controls. Using dansyl
chloride derivatisation, the sensitivity improved considerably; total
estrone and estradiol levels were detectable (albeit low because
the serum donors were male). Total estrone (i.e., free and sulphate)
was in the 1–6 nM range (males) or 5–6 nM (females) in controls,
with the somewhat higher values of 5–16 nM (males) and 5–11 nM
(females) in OE-treated rats. Saponification with KOH raised the
recovery of estrone to 25–32 nM (males) and 33–35 nM (females)
in controls and 49–61 nM (males) and 43–70 nM (females) in OE-
treated rats.
Serum samples (400 L) were extracted and dried as indicated
above, but dissolved in only 0.050 mL of methanol of which 0.04 mL
was injected into the HPLC. These samples allowed us to detect
OE in serum at the limit of sensitivity of the system. The con-
centrations (N = 6) were 10–20 nM for controls and 11–22 nM for
OE-treated rats. These differences were not considered significant
because both ranges were practically superimposed.
2.2.3. OE derivatisation
OE was also derivatised using the Girard P reaction [45]. This
procedure allowed a decrease in the limit of detection of OE
(derivatised) in plasma through HPLC–MS/MS to about 50 nM using
100 L samples of plasma. We used Inertsil ODS3 (Varian) columns
150 mm × 30 mm × 3 m, eluted with (A) 1 g/L formic acid in water
and (B) acetonitrile at a flow of 0.3 mL/min. The method was
checked with standards of deuterated OE and calibration curves
were developed. Using this approach, the levels of OE measured in
a trichloromethane:methanol extract of the plasma of Wistar rats
were in the 20–30 nM range, showing considerable variability and
results that were not different from those of rats that received a
standard oral load of OE. These values were in the same range as
data previously published using a similar extraction–derivatisation
method (ranging from <5 nM to 54 nM in human samples) [46].
The obvious conclusion was that OE was in limited amounts in
normal serum, and the OE gavage did not change its scant presence.
However, the OE load also did not result in a sizeable increase of
estrone, its esters or hydroxylated derivatives.
2.3. Estrone radioimmunoanalysis
2.3.1. Radioimmunoanalysis-based method for serum acyl
estrone esters
The use of a RIA (with an antibody that does not react with
estradiol) to measure the evolved estrone convinced us of the prac-
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Fig. 1. HPLC–MS/MS chromatogram of OE, oleic acid and estrone standards. All separate standards were added at the same concentration, 2.5 M. The conditions for
separation are given in the text. The main breakup fragments are indicated in the figure.
tical identity of OE and “acyl-estrone”, which was reinforced by the
increased levels observed in rats injected with OE [5,12,28].
The use of a specific RIA in the final phase of the analytical
method eliminated, at least theoretically, most of the possible
interferences by other compounds. The only significantly plausi-
ble interference in the use of the specific anti-estrone antibody
(E3153, Sigma) was cross-reactivity with dehydroepiandrosterone
sulphate. This compound was removed from human plasma sam-
ples because of its high levels, but not from most rat samples
because of its much lower concentrations in rat plasma compared
with human plasma [47].
2.3.2. Specificity of antibodies
RIA is a very specific method for analysis of a given molecule in
a complex mixture, provided that the antibody is adequate (reac-
tive, specific, sufficiently high titer, low cross-reactivity). When our
supply of “good” estrone antibody was exhausted, we obtained and
compared all estrone kits and antibodies we were able to find. How-
ever, the low supply and variety of sources of antibodies against
estrone is a problem resulting from estrone no longer being a med-
ically interesting molecule. Estrone is seldom analysed in humans,
and in the recent past, a sizeable number of the few animal studies
using this compound were ours; consequently, the commercially
available supply of antibody is low. In addition, optimised modern
RIA and ELISA methods rely on estrone antibodies raised against
derivatives of the estrone nucleus with side chains attached in the
C5–C6 region. Neither OE nor the estrone freed by the saponifi-
cation of serum from rats pre-loaded with an OE gavage reacted
with these antibodies. The estrone obtained by the saponification
of pure synthetic OE, however, was easily measured using almost
all methods we tested.
Because our early studies have shown the presence of “estrone”
in saponified plasmas (the methodology also detected free estrone,
which we measured using the same setup), but the new (and more
sophisticated) antibodies/kits were not reactive (but they reacted
with free estrone notwithstanding), we assumed that the earlier
(i.e., discontinued) antibody was able to react with an unknown
molecule with a marked structural similarity to estrone. This reac-
tion was not reproduced by the newer and more specific antibodies.
The high cross-reactivity of the old antibody with DHEA and estrone
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sulphate was also not reproduced in the modern kits, which largely
discriminate estrone from estrone sulphate and show low cross-
reactivity with DHEA–sulphate.
The data allow us to postulate that after the saponifica-
tion of organic phase-extracted serum lipophilic fractions, there
was not the expected release of estrone, or at least an estrone
moiety recognisable by the “modern” specific antibodies. How-
ever, the relatively high (in the 0.1 M range) earlier measured
levels of “estrone” suggest that – even provided that reactiv-
ity with real estrone was higher – the levels of this thus far
unknown compound freed by saponification should be fairly high,
at least in the range of our earlier analyses. This unknown entity,
evidently not estrone, must also possess a structure with suf-
ficient similarity to estrone as to confound a relatively specific
antibody.
2.4. In vivo tracer studies with labelled estrone
2.4.1. Plasma label after OE gavages, separation with exclusion
size columns
The OE gavage approach described above (including size and
handling of the animals and samples) was repeated using labelled
OE, which we synthesised from labelled estrone and oleoyl chloride
[3]. Using tritium-labelled estrone (NEN), we produced 3H-OE to
label the gavage doses to a mean specific activity of 1.3 kBq/nmol,
i.e., giving 3.9 MBq of labelled OE to each rat. This way, we obtained
approximately 2.2 kBq/mL in the serum of rats under the standard
gavage conditions described above.
The data calculated from the label content in plasma or serum
(using the specific activity of the gavage dose) were in the low
micromolar range, i.e., more than 3 orders of magnitude higher
than the direct measurements with the HPLC–MS/MS. Evidently,
the tritium label was not attached to OE.
Serum components of rats loaded with 3H-labelled OE were sep-
arated through columns of Sephacryl S200 (Sigma). A small fraction
of the label eluted with high MW proteins (we assumed they were
lipoproteins), but most of the label was eluted in a broad peak run-
ning with the solvent front. This peak did not correspond to OE
or to any other tested estrone derivative. Using Sephadex G100
columns (Sigma), we obtained a small proportion of the label elut-
ing with the front, i.e., with high molecular weight proteins and any
lipophilic compound attached to them. However, most of the label
eluted with the void-volume of the column.
Using the Varian HPLC with a Zorbax GF-250 molecular-sieve
column (4.6 mm × 250 mm, 4 m; Agilent) and a 50 mM phosphate
buffer pH 7.5 containing 150 mM NaCl (0.5 mL/min), we proceeded
to elute crude serum samples from rats that had received a tritium-
labelled OE gavage. The HPLC eluates were counted in 0.2 mL
aliquots in a scintillation counter. Fig. 2 shows the presence of tri-
tium in the eluate fractions. Most of the label was carried practically
with the front; smaller peaks were eluted later, including estrone,
estradiol and several unknowns. The same pattern was observed in
controls and in rats receiving a gavage of only the tracer (no cold
OE). Serum samples with no tritium label were also run through
the HPLC using the same setup, with the eluate being analysed on
line by MS/MS. No significant ion counts were found in the time
fraction corresponding to the massive tritium peak.
Crude serum plasma from rats that had received a gavage of
14C-OE 2 h before sacrifice were run on Sephadex G100 (Sigma)
columns. The distribution of the label can be observed in Fig. 3.
Extraction of the main peak with a SPE C18 cartridge (SEP-PAK,
Waters) resulted in the retention of >99% of the label, which was
quantitatively eluted with methanol. Repeating the same exper-
iment with tritiated-OE, the main peak (coincident in time with
that of 14C-OE and close to the void volume of the column) was
extracted with a SPE C18 cartridge; however, only 13% of the
Fig. 2. Distribution of 3H label in the serum of a male overweight rat 2 h after a
3H-OE gavage. The data correspond to HPLC eluates of sera using a Zorbax GF-250
molecular-sieve column. The crosses and dotted line represent the (log) relation-
ship between molecular weight and elution time obtained from a series of protein
standards.
label was retained, the rest being washed away in the aqueous
fraction. The retained label was again quantitatively eluted with
methanol.
2.4.2. The problem of loss of label from tritium or deuterated
estrone
Saponification of pure deuterium-labelled OE resulted in a sig-
nificant loss of deuterium from the estrone moiety [48]. This was
a consequence of the interchange of D and H from estrone to the
solvent in the highly alkaline medium. We observed similar results
in strongly acidic media used to test the acidic hydrolysis of OE.
Tritium-labelled OE, and free estrone, also lost label to the
medium under extreme pH conditions in highly variable propor-
tions. After oral gavage, a high proportion of OE (essentially the
part of the gavage dose not hydrolysed by esterases and therefore
taken up by the animal) remains in the stomach and its walls [33].
Because stomach pH is in the 0–1 range, we can expect a size-
able interchange of tritium from OE with stomach juices, mainly
water. Because body water interchange is faster than the passage
of lipophilic compounds (OE, estrone), we can expect that a large
Fig. 3. Distribution of label in plasma of rats after receiving gavages of 14C- or
3H-labelled OE eluted from a Sephadex-G100 column. The data are expressed in
fmol/per 1 mL fraction.
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Table 2
Mean plasma concentrations of OE and related compounds 2 h after an oral gavage
dose of 10 nmol/g OE to adult male Wistar rats.
nM
Plasma “estrone” label concentration (Table 1) 413 ± 144
Plasma “acyl-estrone” concentration
(extraction + KOH + RIA)
758 ± 442
Plasma “acyl-estrone” concentration (as above
but discounting estrone sulphate)
576 ± 335
Plasma free estrone (RIA) 0.860 ± 0.026
Plasma estrone sulphate (RIA) 181 ± 38
Plasma free 17-estradiol (RIA) 2.32 ± 0.09
Mean OE concentration in plasma (Gir-P, MS) 61 ± 15
The data correspond to different experimental setups and different animals.
part of body water would become tainted by the tritiated water in
the gut lumen.
Lyophilisation of plasma resulted in the loss of most of its
radioactivity. Distillation in vacuo using Thunberg tubes yielded
tritium-labelled water extracted from plasma. Approximate esti-
mations of the proportion of label present in serum in the form
of tritiated water (or other volatile solvents) were in the range of
78–83%. Assuming a water-accessible volume of water in the rat of
about 75% (i.e., 280 mL for a large male rat) and a gavage of 4 MBq,
the amount of tritiated water formed in 2 h was approximately
477 kBq. This result leads to a mean specific activity of the whole
body water of 1.7 kBq/mL, which is approximately 11.8 ± 4.3% of
the total label in the gavage dose (Table 2). These values are max-
imal and are rough estimations that do not take into account the
faster accessibility of the plasma space and the longer time needed
to reach all corners of intracellular and interstitial water com-
partments. In any case, the high proportion of label found in the
front-running peak agrees with the notion that most of the serum
tritium was in the form of tritiated water.
Consequently, all calculations based on total label content in
plasma (or even those of specific peaks in which the initial spe-
cific activity was used) could no longer be applied because of the
artifactual presence of large amounts of tritiated water (Fig. 4).
2.4.3. Use of 14C-OE in tracer studies
The obvious substitute for tracer studies was 14C-OE. This stable
label had the advantage that no interchange of labile deuterium or
tritium label was possible even under extreme conditions, unless
the molecule itself was destroyed. This approach also allowed for
more precise measurements of radioactivity with only minimal
errors due to quenching. However, use of 14C-OE posed other signif-
icant problems: very scant commercial availability, high cost and
low specific activity (which are consequences of the difficulty in
Fig. 5. Distribution of the 14C label in the plasma of male overweight rats 2 h after
receiving a gavage of 14C-OE. The data correspond to eluates of sera after HPLC using
a Zorbax GF-250 molecular-sieve column. The crosses and dotted line represent the
(log) relationship between MW and elution time obtained from a series of protein
MW standards.
incorporating 14C, usually in the C4 position) and its longer half-life.
However, using the very limited amount of 14C-estrone available
(Tjaden Biosciences, Burlington, IA, USA), the oral-gavage proce-
dures were repeated as described for 3H-OE.
The results, from rat sera chromatography using a Zorbax GF-
250 molecular-sieve column, obtained with 14C-OE, were markedly
different from those of 3H-OE (Fig. 5). Instead of a huge peak in 3H-
OE sera at 7 min we obtained a more flattened 14C-OE sera image,
with a main peak at 8 min and a secondary peak at 6 min. Applica-
tion of a linear protein MW series of standards would give a MW
of about 5 kDa for the 3H-OE rat peak and a similar value for 14C-
OE, plus larger peaks out of range. This is probably a consequence
of the lipophilic retention activity of the Zorbax GF-250 columns
in addition to its simple MW separation. The largest tritium peak
was coincident with the void volume of the column and fully cor-
responds to tritiated water, obscuring the other peaks because of
its size.
Running cold sera of rats receiving the same gavage and treat-
ment (but no label), the MS/MS analysis of the eluates was possible.
Two early small peaks and a broader undefined zone of label distri-
bution eluting late were observed (Figs. 6 and 7). The last zone could
be roughly approximated to estrone, but there was no clear coinci-
Fig. 4. Distribution of plasma estrone and related molecules in male rats after a single oral gavage of OE. The graph on the left presents the values obtained for “acyl-estrone”
(using the extraction, saponification and RIA method), estrone sulphate (RIA), estradiol (RIA) and estrone (RIA) in nM. The graph on the right presents the combined estrone
compounds compared with the calculated label corresponding to tritium water, also in nM.
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Fig. 6. HPLC–MS/MS of a C18 cartridge plasma extract of a rat receiving a plain oil gavage. This is a blank for Fig. 7. The range of masses analysed was 200–600. Fragmentation
spectra for peaks 1–3 are also included.
dence with OE and estrone whatsoever. The more hydrophilic twin
peaks could be associated with very low molecular weights when
compared with a series of protein standards, 10.6 kDa and <4 kDa.
However, these estimations were not fully applicable because the
type of column used is not a perfect molecular weight sieve because
deep adsorption interactions are also produced with lipophilic
compounds. In any case, the most distinct label presence (account-
ing for more than half of the label in the sample) corresponded to
fairly hydrophilic compounds. No 14C label was found associated
with OE and only a small part with estrone.
2.4.4. Low OE levels in rat serum
The MS/MS analysis of these peaks (Figs. 6 and 7) did not show
any fragment similar to that of estrone or OE (nor any other of the
estrogenic compounds tested). The approximate molecular weights
for these peaks were estimated to be at least 2–4 kDa. After MS/MS,
their main fragments (parental: secondary) were (595: 533, 288)
and (306: 219), i.e., they were in part coincident. However, they
were different from those obtained for estrone (271: 253, 156) or OE
(535: 271, 253). As expected, OE showed the same fragmentation as
estrone. Nevertheless, we have no proof that either of these peaks
actually corresponded to the labelled estrone fraction compounds,
that there was a single compound in each peak or that what we
were looking for was sufficiently ionised to be present in the mass
spectrograms.
Notwithstanding, we found that the C18 columns were able to
retain the label from water-diluted serum; the 14C label was then
eluted with methanol (and methanol–water mixtures in propor-
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Fig. 7. HPLC–MS/MS of a C18 cartridge plasma extract of a rat receiving an OE gavage 2 h before extraction. The range of masses analysed was 200–600. Fragmentation
spectra for peaks 1–3 are also included.
tions up to 1:1), which were conditions that maintained estrone
and OE retained in the column. A very approximate calculation of
concentrations from the specific activity of the estrone moiety (as
administered by the gavage) placed the possible concentration of
the labelled compounds in the 0.1 M range (Table 2). However,
precise calculations could not be performed because of the small
sample size, low overall label recovery and limited number of sam-
ples. We also found that when analysing whole blood, the packed
red blood cells retained a significant proportion of the 14C label that
was much more than justified by trapped plasma (about 25–30% of
all blood label).
There were no significant differences in 14C peak size or recov-
ery between the controls and OE-loaded rats, which may in part
be a consequence of the small size of the sample (4 animals each),
the very low recovery of label, the smallness of the peaks and indi-
vidual differences between the rats. The specific activity of sera
ranged from 90 to 180 Bq/mL regardless of having received the
same gavage dose in terms of kBq/g or the rats having a similar
weight.
2.5. Subcellular fraction binding
2.5.1. Nuclear receptor binding of OE-derived label
One approach to clarify the existence of specific OE-derivative
receptors that are different from the estrogen receptors is the devel-
opment of a strategy in which direct binding of the complex OE
derivative-receptor to the cell nucleus is analysed.
OE induces marked changes in the expression of a number of
enzymes and regulatory proteins controlling the metabolism of
energy in liver [19], WAT [18], BAT [17] and other organs, as well as
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the metabolism of cholesterol in liver [49] and the metabolism of
steroid hormones in liver, testicle, adrenals and other organs [50].
WAT is a good target because of the deep changes it experiences
under OE treatment [51], but the large mass of fat and the diversity
of metabolic activity at its sites [52] make the standardisation of
systematic studies with cell organelles difficult. In contrast, liver
is a recurrent target for OE action in a number of diverse mecha-
nisms and is usually the tissue of choice for the isolation of cells and
its organelles because liver has a robust ability to withstand in vitro
manipulation. We decided to use liver cell fractions to further inves-
tigate the mechanism of action of the plasma-carried OE-derived
metabolite, which we considered to be the compound responsible
for the OE-induced metabolic changes.
The standard preparation consisted of three fractions: (a) serum,
obtained from rats receiving a 3H-OE gavage as described above;
(b) nuclei, isolated from otherwise untouched rats; and (c) cytosol
from the same untouched rats, as well as cytosol from the liver cells
of the rats receiving the 3H-OE gavage.
After the rats were sacrificed, their livers were excised and cut
in rough large pieces that were kept in chilled Krebs–Ringer bicar-
bonate buffer supplemented with 0.3 M sucrose [53]. A portion
of the fragments were taken out and homogenised in 5 volumes
of HED buffer (25 mM HEPES, 19 nM NaCl, 1 mM dithiothreitol,
1 mM EDTA) in the cold, using a teflon/glass Potter–Elvejhem
manual homogeniser, and centrifuged for 7 min at 1000 × g.
The precipitate was centrifuged in 2.3 M sucrose for 1 h at
50,000 × g to obtain a clean nuclear pellet. The supernatant of
the first low speed centrifugation was again centrifuged for 1 h at
200,000 × g to obtain a cytosol fraction free of organelles. Other
samples were homogenised with several strokes in an old and
worn Potter–Elvejhem manual homogeniser. The homogenate was
roughly filtered through a double layer of hose and centrifuged
for 5 min at 100 × g, and the nuclear precipitate was washed twice
with buffer and inspected for integrity and homogeneity under the
microscope. The nuclei were gently suspended in buffer and kept
on ice until needed.
Fresh nuclei were incubated with cytosol from 3H-OE-laden rats
(receiving a single 10 nmol OE dose, or 1.7 MBq 3H-OH) for 0 or
120 min at 37 ◦C in a slow moving shaking bath. The final volume
contained 2 mL of nuclei suspension (about 0.8 mg protein), 15 mL
of cytosol extract (about 225 mg protein, which was equivalent to
the total liver aqueous fraction diluted 1:1 with buffer). The con-
trol (time 0) was immediately chilled and centrifuged (30 min at
200,000 × g) to separate the nuclear and cytosol fractions; 120 min
later, the second tube was also chilled in ice and centrifuged. The
nuclei were washed once with 1 mL buffer and then counted. Typi-
cally, time 0 displayed background counts, but after 60 min, a small
amount of label was found attached to the nuclei (in the range
of 2–3% of the cytosol label, amounting to a few hundreds of Bq).
Further washing of the nuclei with buffer did not result in a signifi-
cant loss of the label. However, treatment of the nuclei with DNase
(Sigma) solubilised the label, which was then lost on washing.
Using clean (i.e., not labelled) cytosol laden with 3H-estrone or
estradiol, the binding of label to the nuclei was high. However, the
addition of either estrone or estradiol to cytosols from rats receiving
a tritium-labelled OE gavage did not hamper the binding of the label
by the nuclei; these hormones were able to bind to the estrogen
receptor, but did not interfere with the binding of the labelled OE-
derivative to nuclear DNA because they bound to different receptor
sites in the nucleus.
2.5.2. In vitro exposure of nuclear receptors to labelled OE
Albumin (fatty acid-free, from Sigma) was dissolved in
Krebs–Ringer bicarbonate buffer (1 mL, 35 g/L) and incubated at
room temperature under gentle shaking for 12 h with 5 M OE
(12 kBq of 3H-OE) added in 0.1 mL of methanol under vigorous
shaking to better distribute the microprecipitate. The albumin sus-
pension was cleaned by passing once through a C18 cartridge
(SPE-C18), which retained most of the unattached OE. The specific
activity of labelled OE-laden albumin was 357 Bq/mg protein.
To 2.5 mL cytosol, 1 mL of OE-laden albumin was added and
incubated at 37 ◦C for 1 h. Separation of albumin with a Blue
Sepharose column (Pharmacia) resulted in the retention of 82%
of the label in the albumin, with the rest being transferred to
other cytosol proteins. Incubation of fresh nuclei with this labelled
cytosol, however, resulted in practically no binding of label to the
nuclei, both in time 0 controls and after incubation. Albumin-OE
also did not interfere with the binding of estrone and estradiol when
following the protocol indicated above. The elimination of cytosol
albumin using Blue Sepharose columns did not retain the cytosol
label, which indicates that the OE-derived label in liver cytosol was
not bound to albumin.
These data showed that the OE-derivative was bound specifi-
cally by the nuclei. Therefore, there was a nuclear receptor or a
cytosolic receptor that was able to be transposed to the nucleus.
This binding occurred at a site different from the estrogen recep-
tor(s) to which estradiol and estrone bind, and thus did not
interfere. OE did not bind the estrone receptor when incubated
with nuclei, a fact that was already tested by us when we found
that OE did not bind to the estrogen receptor  [54].
3. Discussion and conclusions
3.1. Differentiation of the effects of OE as pharmacological agent
from those of its derivative W
In spite of OE being a normal component of plasma, the variabil-
ity of its levels and their low entity compared with W suggest that
this is not the real metabolic signal controlling body fat size. This
role is probably played by OE’s derivative, W. The estimated levels
of W change in accordance with the metabolic effects sought by OE
administration.
The nature of the OE-derivative, however, has not yet been elu-
cidated. We were unable to clarify the nature of the OE-derivative
because we painstakingly followed a number of false leads, based
essentially on the “facts”.
(a) OE administration results in a repetitive, dose-dependent chain
of effects deeply altering the metabolism and energy homeosta-
sis [2,55].
(b) The administration of the estrone moiety alone produces, at low
concentration, an effect opposite to that of OE [26]. OE at low
concentrations has the same effect as higher concentration, but
the effects are less marked [56].
(c) -Estradiol administration slightly lowers body weight
[57–59], but not in the same form, intensity and dose-
dependent manner as OE [2]. OE also inhibits the formation of
estradiol by inhibiting estrone 17 oxidation [50].
(d) OE has no marked estrogenic effects (as those of -estradiol)
when given orally [53], but produces hypoandrogenicity
instead [50].
(e) The OE label finds its way easily into the blood and tissues [33],
which is considered proof that it is actually taken up.
(f) “Acyl-estrone” can be measured in plasma with specific anti-
bodies for estrone [25]. Therefore, the final derivative must
travel in plasma in a form in which the estrone nucleus is recog-
nisable.
(g) Estrone is synthesised by adipose tissue in significant amounts
[60]; it is excreted essentially as estrone and a number of its
hydroxylated derivatives [61,62]. The excretion of estrone is so
massive and the molecule is so resistant that it remains in the
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soil and sedimentary strata for long time [63]. Most of the estro-
gens in the market come from conjugates and other derivatives
in the urine of pregnant mares [64].
Of these “facts” only (e) and (f) were not sufficiently proven.
In this study, we have found that they were not completely true.
However, the remaining “facts” stand. Substitution of estrone by
estradiol or other estrogens does not elicit the same results [29].
Thus, OE is effective as a drug against obesity, and OE or W is present
in the body in amounts related to the mass of fat reserves [36,65].
However, OE does not travel in plasma in significant amounts [66],
as found here. Instead, we found a more hydrophilic derivative
that binds liver nuclei and travels in plasma, but whose structure
is largely unknown. We named this compound “W”. We can only
speculate about its concentrations from our early works using a
rather non-specific antibody. We have not been able to prove that
it contains an intact estrone nucleus. If it does not, then why is so
much estrone produced and excreted? Why is so much structural
specificity needed for OE to act as a drug if not as donor of the
estrone nucleus in a form that is not directly accessible by the free
hormone?
The limited, but constant, presence of real OE in plasma is conse-
quent with this molecule being the actual precursor of W, in a way
that is similar to its formation from OE gavages, but not directly
from estrone administrations. The WAT synthesis of OE, its pres-
ence in this tissue and in plasma lipoproteins and its role as W’s
precursor suggest that the making of a WAT tissue mass-dependent
ponderostat signal based on estrone derivatives is a much more
complex affair than previously assumed.
3.2. Postulated nature of the functional OE derivative (W)
The relative hydrophilia of the functional OE derivative points
suggests that estrone is not part of the molecule because the
estrone nucleus is extremely hydrophobic and resistant to chemi-
cal modification. However, we did not find free estrone fragments
in the MS/MS breakup of the purported W peak. Thus, we can
assume that the modification of the estrone nucleus is done
through the most probable (and easy) way, the hydroxyl in C3.
Consequently, the path synthesising W from OE requires the dis-
placement/substitute of the oleoyl moiety. Perhaps this is the
reason why OE is a good precursor of W and free estrone (and other
esters) is not. In any case, if estrone is part of the W molecule (as
we assume), it needs a fairly hydrophilic attachment to compen-
sate for its marked hydrophobicity. The retention of this compound
in C18 columns suggests that the derivative is probably a polarised
molecule, with a hydrophobic region (more or less transformed
estrone nucleus) and a hydrophilic side chain, probably bound on
C3.
Saponification does not free MS/MS-identifiable estrone. Thus,
either the estrone is modified in a way that results in it being
unrecognisable to the MS system using the limited methodology
available, or it is bound to the hydrophilic attachment in a way that
is not susceptible to breakage by saponification and is insensitive to
acyl-cholesterol esterases that easily hydrolyse OE. Alternatively, at
least, W is not broken up by these procedures to yield free estrone.
We can infer that the side chain attachment to estrone is probably
not an ester bond.
The molecular weight of W is relatively low and is probably
lower than OE. However, we cannot speculate further with the
dearth of information (and accumulated disinformation) on the
nature of this compound.
Thus, we can only conclude that:
(a) There is an active OE “derivative”, W, whose complete structure
we do not know but that necessarily has to maintain some rela-
tionship with the original OE molecule (i.e., at least containing
the estrone nucleus) because of structural constrictions and the
above cited general considerations on the role of estrone.
(b) This compound must necessarily travel in the bloodstream to
reach its target organs. Consequently, its concentration must
change with higher loads of the precursor OE. Alternatively, its
levels should parallel the effects observed. Because OE effects
are dose-dependent, those of the derivative must also be dose-
dependent. The changes agree with those of plasma label after
tritium water is discounted.
(c) W belongs to a new class of hormonal signals (of which none
have been described so far), which are derived from steroidal
hormones, and has nuclear receptors different from the estro-
gen receptors.
3.3. Perspectives
OE was developed as an anti-obesity drug. The treatment of a
severely morbid obese human with OE showed dramatic slimming
effects with no secondary effects, nor changes in his plasma chem-
istry or steroid hormone levels [67]. OE was later subjected to more
orthodox clinical trials, with excellent phase I results; however,
phase II did not show sufficiently significant losses of weight in the
experimental subjects. For this reason, the development of OE as a
slimming drug was discontinued, in spite of the results being in the
expected range for the doses given [68]. In spite of this drawback,
investigations to understand how OE induced these peculiar effects
on energy partition have continued. The data presented here sum-
marise the latest efforts to characterise W, the active form of OE.
The eventual uncovering and administration of W (instead of OE) as
an anti-obesity (and anti-diabetic hypocholesterolemic) drug may
retain the powerful positive effects of OE without its inconvenient
loading of estrone and negative effects on testosterone metabolism.
We continue working along this line to establish the complete
chemical nature of this singular compound. Although it is obscured
by many other plasma components, this is an elusive albeit very
important target.
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